Progesterone (Micronized) — Women's Hormones

Bioidentical micronized progesterone for endometrial protection and symptom management in hormone replacement therapy. FDA-approved with Grade A evidence.

Overview

Micronized progesterone (Prometrium) is bioidentical progesterone used in HRT for women with intact uterus. It provides essential endometrial protection when estrogen is prescribed, preventing endometrial hyperplasia and cancer. Unlike synthetic progestins, bioidentical progesterone has favorable effects on sleep, mood, and cardiovascular markers. The REPLENISH and KEEPS studies demonstrate safety and efficacy. Bedtime dosing is preferred due to sedative effects that can improve sleep quality.

Indications

  • Endometrial protection when using systemic estrogen (REQUIRED if uterus intact)
  • Sleep disturbance in perimenopause/menopause
  • Anxiety and mood support during hormone transition
  • Luteal phase support in perimenopause
  • Part of combined HRT regimen

Mechanism of Action

Micronized progesterone absorbed in GI tract; micronization improves bioavailability

Dosing

CompoundDoseFrequencyNotes
Micronized Progesterone (Prometrium)100 mgDaily at bedtimeStandard continuous regimen with estrogen. Prevents breakthrough bleeding after initial months
Micronized Progesterone (Prometrium)200 mgDaily at bedtimeHigher dose for perimenopause with heavier symptoms or as cyclic regimen
Micronized Progesterone (Prometrium)200 mgDays 1-12 of each monthResults in monthly withdrawal bleed. Preferred by some women transitioning into menopause
Progesterone Suppository100-200 mgDaily at bedtimeAlternative if oral not tolerated. Higher uterine levels, lower systemic exposure

Safety & Contraindications

  • Required when using systemic estrogen in women with intact uterus to prevent endometrial hyperplasia
  • Contraindicated with peanut allergy (Prometrium contains peanut oil)
  • May cause drowsiness - take at bedtime
  • Avoid in active thromboembolism or liver disease
  • Bioidentical progesterone has better cardiovascular profile than synthetic progestins
  • Use continuous or cyclic regimen based on patient preference